Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2017

View Archived Issues

Bonti secures series B financing to support development of EB-001

Phase III trial studies Solucin for neuroendocrine tumors of gastroenteric or pancreatic origin

BAY-1895344: a potent candidate for DNA damage-related tumors

New phase III trial explores use of nintedanib in progressive fibrosing lung conditions

Abeome and CDC establish Zika collaboration

Parvus signs license and collaboration agreement with Novartis in type 1 diabetes

A-395 is a first-in-class antagonist of PRC2 protein-protein interactions

H3 Biomedicine identifies selective estrogen receptor covalent antagonist H3B-6545 for breast cancer

Results from the TRUE-AHF trial of ularitide in patients with acute heart failure

Bicycle reports preclinical milestone under ThromboGenics ophthalmology alliance

AbbVie initiates phase III study of ABT-494 for psoriatic arthritis

New chewable tablet formulation of Vyvanse available in U.S.

MedImmune begins first-in-human study of MEDI-5083 alone and with durvalumab in solid tumors

Phase I/IIa trial of FOL-005 demonstrates stimulation of hair growth in healthy volunteers

Vernalis and Servier patent DYRK1 and CLK1 inhibitors

Lion Biotechnologies and MD Anderson establish TIL therapy alliance

Oncochel Therapeutics identifies thiosemicarbazone iron chelators

Oragenics provides update regarding AG-013 and OG-716

Xenon Pharmaceuticals and Genentech present Nav1.7 channel blockers

Johnson & Johnson reports key milestones of first quarter 2017

Incyte discovers Pim kinases inhibitors

Zejula now available in U.S.

BioCryst Pharmaceuticals presents plasma kallikrein inhibitors

Qu Biologics reports response and remission rates from trial of Qbeco in Crohn's disease

PLx Pharma completes merger with Dipexium Pharmaceuticals

Phase III studies of veliparib in NSCLC and TNBC did not meet primary endpoints

Cancer Research UK, CPF and NCI collaborate to target RAS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...